Exact Mass: 345.24344260000004
Exact Mass Matches: 345.24344260000004
Found 334 metabolites which its exact mass value is equals to given mass value 345.24344260000004,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Himbacine
A piperidine alkaloid that is decahydronaphtho[2,3-c]furan-1(3H)-one substituted by a methyl group at position 3 and a 2-[(2R,6S)-1,6-dimethylpiperidin-2-yl]ethenyl group at position 4. It has been isolated from the bark of Australian magnolias. D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics relative retention time with respect to 9-anthracene Carboxylic Acid is 0.814 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.809
Rosmaricine
C20H27NO4 (345.19399820000007)
Rosmaricine is found in herbs and spices. Rosmaricine is isolated from rosemary (Rosmarinus officinalis) using NH3 during extraction. Isolated from rosemary (Rosmarinus officinalis) using NH3 during extraction. Rosmaricine is found in herbs and spices and rosemary.
Eicosapentaenoyl Ethanolamide
Eicosapentaenoyl Ethanolamide (EPEA) is an endogenous fatty acid amide. EPEA is metabolized by fatty acid amide hydrolase (FAAH) and N-acylethanolamine-hydrolyzing acid amidase (NAAA), the latter of which has more specificity toward PEA over other fatty acid amides. DHEA and eicosapentaenoyl ethanolamide (EPEA) bind to the CB1 receptor in rat brains.23 DHA levels in the mouse brain have been shown to inversely affect the levels of 2AG. Eicosapentaenoyl Ethanolamide (EPEA) is an endogenous fatty acid amide.
3-hydroxyundecanoyl carnitine
C18H35NO5 (345.25151000000005)
3-Hydroxyundecanoyl carnitine is an acylcarnitine. More specifically, it is an 3-hydroxyundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxyundecanoyl carnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxyundecanoyl carnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Bevantolol
C20H27NO4 (345.19399820000007)
Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors. C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AB - Beta blocking agents, selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
Sebacoyl-L-carnitine
C17H31NO6 (345.21512659999996)
Sebacoyl-L-carnitine is an acylcarnitine. More specifically, it is an sebacic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Sebacoyl-L-carnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Sebacoyl-L-carnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Methylnonanedioylcarnitine
C17H31NO6 (345.21512659999996)
3-Methylnonanedioylcarnitine is an acylcarnitine. More specifically, it is an 3-methylnonanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Methylnonanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Methylnonanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
8-Hydroxyundecanoylcarnitine
C18H35NO5 (345.25151000000005)
8-Hydroxyundecanoylcarnitine is an acylcarnitine. More specifically, it is an 8-hydroxyundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-Hydroxyundecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 8-Hydroxyundecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
5-Hydroxyundecanoylcarnitine
C18H35NO5 (345.25151000000005)
5-Hydroxyundecanoylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxyundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxyundecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxyundecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
2-Hydroxyundecanoylcarnitine
C18H35NO5 (345.25151000000005)
2-Hydroxyundecanoylcarnitine is an acylcarnitine. More specifically, it is an 2-hydroxyundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Hydroxyundecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-Hydroxyundecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
9-Hydroxyundecanoylcarnitine
C18H35NO5 (345.25151000000005)
9-Hydroxyundecanoylcarnitine is an acylcarnitine. More specifically, it is an 9-hydroxyundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-Hydroxyundecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 9-Hydroxyundecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
6-Hydroxyundecanoylcarnitine
C18H35NO5 (345.25151000000005)
6-Hydroxyundecanoylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxyundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Hydroxyundecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Hydroxyundecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
7-Hydroxyundecanoylcarnitine
C18H35NO5 (345.25151000000005)
7-Hydroxyundecanoylcarnitine is an acylcarnitine. More specifically, it is an 7-hydroxyundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Hydroxyundecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-Hydroxyundecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
10-Hydroxyundecanoylcarnitine
C18H35NO5 (345.25151000000005)
10-Hydroxyundecanoylcarnitine is an acylcarnitine. More specifically, it is an 10-hydroxyundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-Hydroxyundecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 10-Hydroxyundecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
4-Hydroxyundecanoylcarnitine
C18H35NO5 (345.25151000000005)
4-Hydroxyundecanoylcarnitine is an acylcarnitine. More specifically, it is an 4-hydroxyundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Hydroxyundecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Hydroxyundecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
5-Nitroxystearic acid
C18H35NO5 (345.25151000000005)
2-[4-[4-(4-Carbamimidoylphenyl)piperazin-1-yl]piperidin-1-yl]acetic acid
C18H27N5O2 (345.21646419999996)
1-Piperidinepropanol, alpha-cyclohexyl-4-(3-hydroxyphenyl)-3,4-dimethyl-
4-Phenyl-1-(3-(tetrahydro-2-furyl)propyl)isonipecotic acid ethyl ester
(E)-(4-Hydroxy-3-methoxycinnamoyl)epilupinine
C20H27NO4 (345.19399820000007)
(2E)-11-(4-aminophenyl)-5,9-O-cyclo-4,6,8-trimethyl-11-oxo-undec-2-enoic acid
C20H27NO4 (345.19399820000007)
2,13-dimethoxy-13,16-cyclo-12,16-seco-kesselringan-11-ol|5,6a-dimethoxy-1-methyl-1,2,3,7,8,9,10,11,12,12a-decahydro-6aH-benzo[4,5]furo[4,3,2:4,5]naphtho[1,8-bc]pyridin-8-ol|Luteicin|luteicine
C20H27NO4 (345.19399820000007)
Holidinine|robustinine|Robustivine
C20H27NO4 (345.19399820000007)
7-O-Aethyl-lycorenin|7alpha-ethoxy-9,10-dimethoxy-1-methyl-lycoran-4(12)-ene|O-ethyl-lycorenine|O-ethyllycorenine
C20H27NO4 (345.19399820000007)
3-(3-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-tropane|5-Tropyloxy-3-methyl-dibenzo-1.3.5-cycloheptatrien|5-Tropyloxy-3-methyldibenzo-1,3,5-cycloheptatrien
20-Oxime-(17alphaOH)-17-Hydroxypregn-4-ene-3,20-dione
(19R)-16beta,19-dihydroxy-(5beta,10alpha)-3-aza-3alpha,19-cyclo-4a-homo-pregnan-21-oic acid 16-lactone|Cycloneosamandaridin
Ala Ala Gly Lys
Ala Ala Lys Gly
Ala Gly Ala Lys
Ala Gly Lys Ala
Ala Lys Ala Gly
Ala Lys Gly Ala
Gly Ala Ala Lys
Gly Ala Lys Ala
Gly Lys Ala Ala
bevantolol
C20H27NO4 (345.19399820000007)
C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AB - Beta blocking agents, selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
Rosmaricine
C20H27NO4 (345.19399820000007)
N-jasmonoyl-dopamine
C20H27NO4 (345.19399820000007)
CAR 10:1;O2
C17H31NO6 (345.21512659999996)
TERT-BUTYL 4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)INDOLINE-1-CARBOXYLATE
C19H28BNO4 (345.21112780000004)
1-(3,7-dimethyloctyl)-1-prop-2-enyl-3,4,5,6-tetrahydro-2H-pyridine bro mide
C18H36BrN (345.20309560000004)
6-AMINO-3-(4-METHYL-PIPERAZIN-1-YLMETHYL)-INDAZOLE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
C18H27N5O2 (345.21646419999996)
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-phenyl-3-propanoyloxypropanoate
C20H27NO4 (345.19399820000007)
2-ETHYLHEXYL ALPHA-CYANO-3,4-DIMETHOXYCINNAMATE
C20H27NO4 (345.19399820000007)
Dicyclomine hydrochloride
C19H36ClNO2 (345.24344260000004)
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent Dicyclomine hydrochloride is a potent and orally active muscarinic cholinergic receptors antagonist. Dicyclomine hydrochloride shows high affinity for muscarinic M1 receptor subtype (Ki=5.1 nM) and M2 receptor subtype (Ki=54.6 nM) in brush-border membrane and basal plasma membranes, respectively[1]. Dicyclomine is an antispasmodic agent and relieves smooth muscle spasm of the gastrointestinal tract in vivo[2].
tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indoline-1-carboxylate
C19H28BNO4 (345.21112780000004)
7-Ethano-1H-isoindole-1, 3(2H)-dion, 2-(2-ethylhexyl)-3a,4,7,7a-tetrahydro-4-methyl-7-(1-methylethy4
4-(3-(Piperidin-1-yl)propoxy)phenylboronic acid, pinacol ester
C20H32BNO3 (345.24751119999996)
tert-Butyl 4-(1-benzylpyrrolidin-3-yl)piperazine-1-carboxylate
N-BOC-isoindoline-4-boronic acid, pinacol ester
C19H28BNO4 (345.21112780000004)
Ethyl 3-Oxo-4-aza-5α-androst-1-ene-17β-carboxylate
tert-Butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindoline-2-carboxylate
C19H28BNO4 (345.21112780000004)
N-(2-hydroxyethyl)-N-(2-hydroxytetradecyl)beta-alanine
C19H39NO4 (345.28789340000003)
2-(1-(TERT-BUTOXYCARBONYL)-2,3-DIHYDROSPIRO[INDENE-1,4-PIPERIDIN]-3-YL)ACETIC ACID
C20H27NO4 (345.19399820000007)
4-(1,3-benzodioxol-5-ylmethyl)-N-cyclohexylpiperazine-1-carboxamide
C19H27N3O3 (345.20523119999996)
(+)-Himbacine
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics
(7Z,10Z,13R,14E,16Z,19Z)-13-hydroxydocosapentaenoate
A polyunsaturated fatty acid anion that is the conjugate base of (13R)-hydroxy-(7Z,10Z,14E,16Z,19Z)-docosapentaenoic acid, arising from deprotonation of the carboxylic acid group; major species at pH 7.3. It is an intermediate in 13-series resolvins biosynthesis from DPA (omega-3).
(2S)-6-amino-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]propanoyl]amino]hexanoic Acid
1-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)pyrrolidine-2,5-dione
C19H27N3O3 (345.20523119999996)
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists
4-[2-(2,6-Dimethyl-1-piperidinyl)-2-oxoethyl]-1-methyl-5-pyrrolo[3,2-b]pyrrolecarboxylic acid ethyl ester
C19H27N3O3 (345.20523119999996)
1-Tert-butyl-6-methyl-3-(1-naphthalenylmethyl)-4-pyrazolo[3,4-d]pyrimidinamine
2-phenyl-N-(3-(piperidin-1-yl)propyl)quinolin-4-amine
N-(cyclohexylmethyl)-6-phenyl-3-(2-pyridinyl)-1,2,4-triazin-5-amine
2-(2-methoxyethyl)-7-[oxo-(4-propyl-1-piperazinyl)methyl]-3H-isoindol-1-one
C19H27N3O3 (345.20523119999996)
4-methyl-N-(3-morpholin-4-ylpropyl)-3-(2-oxopyrrolidin-1-yl)benzamide
C19H27N3O3 (345.20523119999996)
(2R,4S)-4-cyclohexyl-2-[[4-(hydroxymethyl)phenyl]methoxy]-3,4-dihydro-2H-pyran-6-carboxamide
C20H27NO4 (345.19399820000007)
[1-(Cyclohexylmethyl)-3-piperidinyl]-(3,4-dimethoxyphenyl)methanone
(7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-7,10,13,16-tetraenoate
(4Z,7Z,10Z,13Z,16Z)-20-hydroxydocosa-4,7,10,13,16-pentaenoate
(7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-7,10,13-trienoate
(7Z,10Z)-12-{3-[(2Z,5Z)-octa-2,5-dien-1-yl]oxiran-2-yl}dodeca-7,10-dienoate
(7Z)-9-{3-[(2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl]oxiran-2-yl}non-7-enoate
2-{[1,1-bi(cyclohexyl)-1-ylcarbonyl]oxy}-N,N-diethylethanaminium chloride
C19H36ClNO2 (345.24344260000004)
(2S,3R)-2-(hydroxymethyl)-6-(1-oxopropyl)-3-phenyl-N-propan-2-yl-1,6-diazaspiro[3.3]heptane-1-carboxamide
C19H27N3O3 (345.20523119999996)
(2S,3S)-2-(hydroxymethyl)-6-(1-oxopropyl)-3-phenyl-N-propan-2-yl-1,6-diazaspiro[3.3]heptane-1-carboxamide
C19H27N3O3 (345.20523119999996)
12-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]dodecanoate
Sebacoyl-L-carnitine, analytical standard
C17H31NO6 (345.21512659999996)
(8E,10Z,13Z,16Z,19Z)-7-hydroxydocosa-8,10,13,16,19-pentaenoate
(4Z,7Z,10Z,12E,14S,16Z)-14-hydroxydocosa-4,7,10,12,16-pentaenoate
(11R)-11-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxydodecanoate
Diamino-(carboxymethyl)-[3-(dodecanoylamino)propyl]azanium
C17H37N4O3+ (345.28655119999996)
DI-Tert-butyl 2-phenyl-1-pyrroline-trans-3,4-dicarboxylate
C20H27NO4 (345.19399820000007)
(5Z,8Z,11Z,14Z,17Z)-icosapentaenoylethanolamine
An N-acylethanolamine 20:5 that is the ethanolamide of (5Z,8Z,11Z,14Z17Z)-eicosapentaenoic acid.
2-[4-[4-(4-Carbamimidoylphenyl)piperazin-1-yl]piperidin-1-yl]acetic acid
C18H27N5O2 (345.21646419999996)
O-sebacoylcarnitine
C17H31NO6 (345.21512659999996)
An O-acylcarnitine having sebacoyl as the acyl substituent.
(7Z,10Z,13Z,16Z)-19,20-epoxydocosatetraenoate
A docosanoid anion that is the conjugate base of (7Z,10Z,13Z,16Z)-19,20-epoxydocosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3
(7Z,10Z,13Z,19Z)-16,17-epoxydocosatetraenoate
A docosanoid anion that is the conjugate base of (7Z,10Z,13Z,19Z)-16,17-epoxydocosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(7Z,10Z,16Z,19Z)-13,14-epoxydocosatetraenoate
A docosanoid anion that is the conjugate base of (7Z,10Z,16Z,19Z)-13,14-epoxydocosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(7Z,13Z,16Z,19Z)-10,11-epoxydocosatetraenoate
A docosanoid anion that is the conjugate base of (7Z,13Z,16Z,19Z)-10,11-epoxydocosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(4Z,7Z,10Z,12E,14S,16Z)-14-hydroxydocosapentaenoate
A hydroxydocosapentaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14S,16Z)-14-hydroxydocosapentaenoic acid, arising from deprotonation of the carboxy group; major species at pH 7.3.
(8E,10Z,13Z,16Z,19Z)-7-hydroxydocosapentaenoate
A hydroxydocosahexaenoate that is the conjugate base of (8E,10Z,13Z,16Z,19Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(4Z,7Z,10Z,13Z,16Z)-20-hydroxydocosapentaenoate
A docosanoid anion that is the conjugate base of (4Z,7Z,10Z,13Z,16Z)-20-hydroxydocosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
oscr#20(1-)
A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#20, obtained by deprotonation of the carboxy group; major species at pH 7.3.
LY255582
LY255582 is a pan-opioid antagonist and has high affinity for mu, delta, and kappa receptors (Ki: 0.4 nM, 5.2, 2.0 nM respectively). LY255582 can decrease food intake and body weight. LY255582 can be used for the research of obesity[1][2][3][4].
3-{14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadec-3-en-2-yl}propanoic acid
13-[3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridecan-5-one
C18H35NO5 (345.25151000000005)
(1r,2s,11r,12r,15s,16r,18r)-12-[(1s)-1-hydroxyethyl]-14,20-dioxa-6-azahexacyclo[16.2.1.0¹,⁶.0²,¹⁰.0²,¹⁶.0¹¹,¹⁵]henicos-9-en-13-one
C20H27NO4 (345.19399820000007)
(1s)-octahydro-1h-quinolizin-1-ylmethyl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
C20H27NO4 (345.19399820000007)
(1s,5s,6r,8r,9s,11r,13r,14s,15s,16r,17s,18s,19r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-6,13,15,19-tetrol
C20H27NO4 (345.19399820000007)
(2s)-1-{[(3r,3as,6ar,9ar,9bs)-6,9-dimethylidene-2-oxo-octahydro-3h-azuleno[4,5-b]furan-3-yl]methyl}pyrrolidine-2-carboxylic acid
C20H27NO4 (345.19399820000007)
(7z)-5-methoxy-8-methyl-11-(6-methylhept-5-en-2-yl)-13-oxa-2-azatricyclo[8.2.1.0⁴,¹²]trideca-2,4(12),7-trien-3-ol
13-[3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridecan-4-one
C18H35NO5 (345.25151000000005)
4,12,14-trihydroxy-5-isopropyl-6,9-dimethyl-15-azatetracyclo[7.6.1.0²,⁶.0¹³,¹⁶]hexadeca-1,13(16),14-trien-3-one
C20H27NO4 (345.19399820000007)
(1r,3r,4s,5r,8r,9s,11s,13r,14s,16s,17r,18r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,4,13,18-tetrol
C20H27NO4 (345.19399820000007)
methyl 3-[(1s,2s,3r,7s,10r,12r,13s)-13-isopropyl-1-methyl-11-azapentacyclo[8.5.0.0²,¹².0³,⁷.0⁷,¹¹]pentadecan-2-yl]propanoate
1-{[(3as,6ar,9ar,9bs)-6,9-dimethylidene-2-oxo-octahydro-3h-azuleno[4,5-b]furan-3-yl]methyl}pyrrolidine-2-carboxylic acid
C20H27NO4 (345.19399820000007)
4,5,17-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-6-ol
C20H27NO4 (345.19399820000007)
5,8-dimethoxy-13-methyl-6-oxa-13-azapentacyclo[8.6.2.1¹,⁵.0⁷,¹⁷.0¹⁴,¹⁸]nonadeca-7(17),8,10(18)-trien-4-ol
C20H27NO4 (345.19399820000007)
(2S)-1-[[(3R,3aS,6aR,9aR,9bS)-2-keto-6,9-dimethylene-3a,4,5,6a,7,8,9a,9b-octahydro-3H-azuleno[5,4-d]furan-3-yl]methyl]proline
C20H27NO4 (345.19399820000007)
{"Ingredient_id": "HBIN006567","Ingredient_name": "(2S)-1-[[(3R,3aS,6aR,9aR,9bS)-2-keto-6,9-dimethylene-3a,4,5,6a,7,8,9a,9b-octahydro-3H-azuleno[5,4-d]furan-3-yl]methyl]proline","Alias": "(2S)-1-[[(3R,3aS,6aR,9aR,9bS)-6,9-dimethylidene-2-oxo-3a,4,5,6a,7,8,9a,9b-octahydro-3H-azuleno[5,4-d]furan-3-yl]methyl]pyrrolidine-2-carboxylic acid; (2S)-1-[[(3R,3aS,6aR,9aR,9bS)-6,9-dimethylene-2-oxo-3a,4,5,6a,7,8,9a,9b-octahydro-3H-azuleno[5,4-d]furan-3-yl]methyl]-2-pyrrolidinecarboxylic acid; (2S)-1-[[(3R,3aS,6aR,9aR,9bS)-6,9-dimethylene-2-oxo-3a,4,5,6a,7,8,9a,9b-octahydro-3H-azuleno[5,4-d]furan-3-yl]methyl]pyrrolidine-2-carboxylic acid","Ingredient_formula": "C20H27NO4","Ingredient_Smile": "NA","Ingredient_weight": "345.43","OB_score": "20.90306639","CAS_id": "126209-82-3","SymMap_id": "SMIT10448","TCMID_id": "NA","TCMSP_id": "MOL009296","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
7-deoxycephalofortuneine
C20H27NO4 (345.19399820000007)
{"Ingredient_id": "HBIN013159","Ingredient_name": "7-deoxycephalofortuneine","Alias": "NA","Ingredient_formula": "C20H27NO4","Ingredient_Smile": "COC1CC23C(=CC1O)CCN2CCCC4=CC(=C(C=C34)OC)OC","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "5159","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(1r,2s,3s,5s,8r,9s,11s,13r,14s,16s,17r,18s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-2,3,13,18-tetrol
C20H27NO4 (345.19399820000007)
13-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridecan-4-one
C18H35NO5 (345.25151000000005)
(1s,17s)-5,6,17-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2,4,6,14-tetraen-4-ol
C20H27NO4 (345.19399820000007)
4,5,17-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-16-ol
C20H27NO4 (345.19399820000007)
(1s,2s,6r,7s,10r,11r)-13-(2-hydroxyethyl)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-6-ol
n-[2-(3,4-dihydroxyphenyl)ethyl]-2-[(1r,2r)-3-oxo-2-[(2z)-pent-2-en-1-yl]cyclopentyl]ethanimidic acid
C20H27NO4 (345.19399820000007)
3-[(2r,5s)-3,6-dihydroxy-5-(2-methylpropyl)-2,5-dihydropyrazin-2-yl]-n-(2-phenylethyl)propanimidic acid
C19H27N3O3 (345.20523119999996)
(1s,2s,4r,6r,7r,10r,11s)-13-(2-hydroxyethyl)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-6-ol
(1's,3s,3's,7's)-1,4',4',14'-tetramethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione
C19H27N3O3 (345.20523119999996)
(1s,3s,5r,8s,9r,10s,11r,14r,16s,17r,18s,19r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,9,10,19-tetrol
C20H27NO4 (345.19399820000007)
5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-6,13,15,19-tetrol
C20H27NO4 (345.19399820000007)
(1r,9s,10s,12r)-4,5,12-trimethoxy-17-methyl-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2(7),3,5-trien-13-one
C20H27NO4 (345.19399820000007)
methyl 3-{13-isopropyl-1-methyl-11-azapentacyclo[8.5.0.0²,¹².0³,⁷.0⁷,¹¹]pentadecan-2-yl}propanoate
(6e)-2-(dimethylamino)-1-(4-hydroxyphenyl)-8,10-dimethyldodec-6-en-3-one
(1s,2s,4s,6r,7s,10r,11r)-13-(2-hydroxyethyl)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-6-ol
methyl 5-ethyl-2-(hydroxymethyl)-6-azapentacyclo[9.5.1.0¹,⁵.0²,⁸.0¹⁴,¹⁷]heptadec-11(17)-ene-15-carboxylate
(2r)-1-{[(3r,3as,6ar,9ar,9bs)-6,9-dimethylidene-2-oxo-octahydro-3h-azuleno[4,5-b]furan-3-yl]methyl}pyrrolidine-2-carboxylic acid
C20H27NO4 (345.19399820000007)
(1'r,3s,3's,7's,12's)-13'-hydroxy-1,4',4',12'-tetramethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecan]-13'-ene-2,5-dione
C19H27N3O3 (345.20523119999996)
methyl 3-[(1r,2r,3s,10s,12s,13r)-13-isopropyl-1-methyl-11-azapentacyclo[8.5.0.0²,¹².0³,⁷.0⁷,¹¹]pentadecan-2-yl]propanoate
(2e,7e)-tetradeca-2,7-dien-1-yl 4-amino-3-hydroxybenzoate
3-[(2s,5r)-3,6-dihydroxy-5-(2-methylpropyl)-2,5-dihydropyrazin-2-yl]-n-(2-phenylethyl)propanimidic acid
C19H27N3O3 (345.20523119999996)
(2r,3s,4s,6s)-2-(hydroxymethyl)-6-(2-hydroxytridecyl)piperidine-3,4-diol
C19H39NO4 (345.28789340000003)
octahydro-1h-quinolizin-1-ylmethyl 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
C20H27NO4 (345.19399820000007)
5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,4,13,18-tetrol
C20H27NO4 (345.19399820000007)
(2e,4r,5s,6s,8r)-4,5,8-trihydroxy-n-[(2s,3s)-1-hydroxy-3-methylpentan-2-yl]-4,6-dimethyldec-2-enimidic acid
C18H35NO5 (345.25151000000005)
4,5,12-trimethoxy-17-methyl-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2(7),3,5-trien-13-one
C20H27NO4 (345.19399820000007)
(2e)-4-[(2s,3r,5r,6s)-6-[2-(4-aminophenyl)-2-oxoethyl]-3,5-dimethyloxan-2-yl]pent-2-enoic acid
C20H27NO4 (345.19399820000007)
(2s,5s,10r,13s,14s,17s,18s)-4-ethyl-10-methyl-6-oxa-4-azaheptacyclo[15.2.1.0²,⁷.0²,¹¹.0³,¹³.0⁵,¹⁰.0¹⁴,¹⁹]icosane-14,18-diol
(3s,3ar,4r,8ar,9as)-4-[(1e)-2-[(2s,6r)-1,6-dimethylpiperidin-2-yl]ethenyl]-3-methyl-decahydro-3h-naphtho[2,3-c]furan-1-one
(2s,3s,5r,6r,9s,11s,16r,17s,18s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-2,3,6,18-tetrol
C20H27NO4 (345.19399820000007)
(1s,16s,17r)-4,5,17-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-16-ol
C20H27NO4 (345.19399820000007)
13-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridecan-4-one
C18H35NO5 (345.25151000000005)
5,6,17-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2,4,6,14-tetraen-4-ol
C20H27NO4 (345.19399820000007)
3-[(2r,5r)-3,6-dihydroxy-5-(2-methylpropyl)-2,5-dihydropyrazin-2-yl]-n-(2-phenylethyl)propanimidic acid
C19H27N3O3 (345.20523119999996)
5-hydroxy-4',4',12',14'-tetramethyl-4h-9',14'-diazaspiro[pyrrole-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,13'-dione
C19H27N3O3 (345.20523119999996)
2-(dimethylamino)-1-(4-hydroxyphenyl)-8,10-dimethyldodec-6-en-3-one
4,5,8-trihydroxy-n-(1-hydroxy-3-methylpentan-2-yl)-4,6-dimethyldec-2-enimidic acid
C18H35NO5 (345.25151000000005)
(2s)-1-{[(3as)-6,9-dimethylidene-2-oxo-octahydro-3h-azuleno[4,5-b]furan-3-yl]methyl}pyrrolidine-2-carboxylic acid
C20H27NO4 (345.19399820000007)
(3e,7e)-n-(3,4-dihydroxybutyl)-2,6,9-trihydroxy-4,8-dimethylundeca-3,7-dienimidic acid
C17H31NO6 (345.21512659999996)
13'-hydroxy-1,4',4',12'-tetramethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecan]-13'-ene-2,5-dione
C19H27N3O3 (345.20523119999996)
13-(2-hydroxyethyl)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-6-ol
4,5,6-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-17-ol
C20H27NO4 (345.19399820000007)
5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,6,10,19-tetrol
C20H27NO4 (345.19399820000007)
(1s,9ar)-octahydro-1h-quinolizin-1-ylmethyl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
C20H27NO4 (345.19399820000007)
4-{6-[2-(4-aminophenyl)-2-oxoethyl]-3,5-dimethyloxan-2-yl}pent-2-enoic acid
C20H27NO4 (345.19399820000007)
3-[3,6-dihydroxy-5-(2-methylpropyl)-2,5-dihydropyrazin-2-yl]-n-(2-phenylethyl)propanimidic acid
C19H27N3O3 (345.20523119999996)
5,9-dimethoxy-14-methyl-7-oxa-14-azapentacyclo[9.6.2.0¹,⁶.0⁸,¹⁸.0¹⁵,¹⁹]nonadeca-8(18),9,11(19)-trien-4-ol
C20H27NO4 (345.19399820000007)
(1s,17s)-4,5,6-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-17-ol
C20H27NO4 (345.19399820000007)
3-[(2s,5s)-3,6-dihydroxy-5-(2-methylpropyl)-2,5-dihydropyrazin-2-yl]-n-(2-phenylethyl)propanimidic acid
C19H27N3O3 (345.20523119999996)
(4r,5r,6r,9r,12s)-4,12,14-trihydroxy-5-isopropyl-6,9-dimethyl-15-azatetracyclo[7.6.1.0²,⁶.0¹³,¹⁶]hexadeca-1,13(16),14-trien-3-one
C20H27NO4 (345.19399820000007)
4-[(1e)-2-(1,6-dimethylpiperidin-2-yl)ethenyl]-3-methyl-decahydro-3h-naphtho[2,3-c]furan-1-one
n-[2-(3,4-dihydroxyphenyl)ethyl]-2-[3-oxo-2-(pent-2-en-1-yl)cyclopentyl]ethanimidic acid
C20H27NO4 (345.19399820000007)
n-(3,4-dihydroxybutyl)-2,8,9-trihydroxy-4,8-dimethylundeca-3,6-dienimidic acid
C17H31NO6 (345.21512659999996)
8-ethoxy-4,5-dimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2,4,6,12-tetraene
C20H27NO4 (345.19399820000007)
(1r,4r,5s,14s)-5,8-dimethoxy-13-methyl-6-oxa-13-azapentacyclo[8.6.2.1¹,⁵.0⁷,¹⁷.0¹⁴,¹⁸]nonadeca-7(17),8,10(18)-trien-4-ol
C20H27NO4 (345.19399820000007)
(1s,3r,5r,6s,8r,9s,10s,11r,14r,16s,17s,18r,19r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,6,10,19-tetrol
C20H27NO4 (345.19399820000007)
1-({6,9-dimethylidene-2-oxo-octahydro-3h-azuleno[4,5-b]furan-3-yl}methyl)pyrrolidine-2-carboxylic acid
C20H27NO4 (345.19399820000007)
(1'r,3s,3's,7's,12's)-5-hydroxy-4',4',12',14'-tetramethyl-4h-9',14'-diazaspiro[pyrrole-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,13'-dione
C19H27N3O3 (345.20523119999996)
(3as,6ar,8s,9ar,9bs)-3,6,9-trimethylidene-2-oxo-octahydroazuleno[4,5-b]furan-8-yl (2s)-2-amino-3-methylbutanoate
C20H27NO4 (345.19399820000007)
(2s)-n-[(2s)-1-(acetyloxy)-3-(1h-indol-3-yl)propan-2-yl]-3-methyl-2-(methylamino)butanimidic acid
C19H27N3O3 (345.20523119999996)
13-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridecan-5-one
C18H35NO5 (345.25151000000005)
1,4',4',14'-tetramethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione
C19H27N3O3 (345.20523119999996)
3-[(1s,2r,3r,7r,10s,11r,13s,14r)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl]propanoic acid
(1r,2s,3s,5s,6r,8r,9s,11s,14s,16s,17s,18s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-2,3,6,18-tetrol
C20H27NO4 (345.19399820000007)
({[(3s)-6-amino-3-{[(2s)-2-amino-1-hydroxy-4-methylpentylidene]amino}-1-hydroxyhexylidene]amino}(methyl)amino)acetic acid
(1s,8s,10r,17s)-8-ethoxy-4,5-dimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2,4,6,12-tetraene
C20H27NO4 (345.19399820000007)
3-[(1r,2r,7s,10r,13r,14s)-14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadec-3-en-2-yl]propanoic acid
n-(3,4-dihydroxybutyl)-2,6,9-trihydroxy-4,8-dimethylundeca-3,7-dienimidic acid
C17H31NO6 (345.21512659999996)
3-[(1s,2r,7r,10s,14r)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl]propanoic acid
(3e,6e)-n-(3,4-dihydroxybutyl)-2,8,9-trihydroxy-4,8-dimethylundeca-3,6-dienimidic acid
C17H31NO6 (345.21512659999996)
13-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridecan-5-one
C18H35NO5 (345.25151000000005)
(1r,3r,4r,5r,8r,9s,11s,13r,14s,16s,17r,18r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,4,13,18-tetrol
C20H27NO4 (345.19399820000007)
(1s,17s)-4,5,17-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-6-ol
C20H27NO4 (345.19399820000007)
[({6-amino-3-[(2-amino-1-hydroxy-4-methylpentylidene)amino]-1-hydroxyhexylidene}amino)(methyl)amino]acetic acid
(2r,3r)-3-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-1-phenoxybutan-2-ol
C20H27NO4 (345.19399820000007)
methyl (1r,2r,5s,8s,14r,15r)-5-ethyl-2-(hydroxymethyl)-6-azapentacyclo[9.5.1.0¹,⁵.0²,⁸.0¹⁴,¹⁷]heptadec-11(17)-ene-15-carboxylate
12-hydroxy-12-(hydroxymethyl)-5,7-dimethyl-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecan-11-one
3,6,9-trimethylidene-2-oxo-octahydroazuleno[4,5-b]furan-8-yl 2-amino-3-methylbutanoate
C20H27NO4 (345.19399820000007)